Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Toxicity of Blinatumomab in the French Compassionate Use Program (ATU) for Adult Patients With B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Refractory, in Relapse, or With Positive Minimal Residual Disease.

NCT03751072 is registered in ClinicalTrials.gov with Group for Research in Adult Acute Lymphoblastic Leukemia as lead sponsor.

NCT NCT03751072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03751072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Toxicity of Blinatumomab in the French Compassionate Use Program (ATU) for Adult Patients With B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Refractory, in Relapse, or With Positive Minimal Residual Disease.
Lead sponsor
Group for Research in Adult Acute Lymphoblastic Leukemia
Phase
Observational
Overall status
Completed
Start date
July 16, 2018
Completion date
January 30, 2019
Enrollment
92 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia with failed remission, acute lymphoblastic leukemia, in relapse